Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Hibiscus wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Hibiscus and MitoQ have evidence — compare verdict strength side-by-side.
250–450 mg standardized extract OR 1.25–2.5 g dried calyx per serving (as tea)
With meals, 2–3 times daily, Morning and afternoon preferred
Standardized extract capsule (anthocyanins ≥10%)
10-20mg daily
morning
Oral capsule (mitoquinol mesylate, 10-20 mg)
4–6 weeks
6–8 weeks
Acute to 2 weeks
4–8 weeks
Acute to 6 weeks
4 weeks
12 months
3 weeks
Efficacy and safety of Hibiscus sabdariffa in cardiometabolic health: An overview of reviews and updated dose-response meta-analysis.
Complementary therapies in medicine (2025) · Meta analysis
Overview of systematic reviews and updated dose-response meta-analysis confirms cardiometabolic benefits of Hibiscus sabdariffa
A systematic review and meta-analysis of the effects of Hibiscus sabdariffa on blood pressure and cardiometabolic markers.
Nutrition reviews (2022) · Meta analysis
Hibiscus significantly reduced systolic BP by −7.10 mmHg (95%CI −13.00 to −1.20) versus placebo
Efficacy of Hibiscus sabdariffa on Reducing Blood Pressure in Patients With Mild-to-Moderate Hypertension: A Systematic Review and Meta-Analysis of Published Randomized Controlled Trials.
Journal of cardiovascular pharmacology (2022) · Meta analysis
13 RCTs (1205 participants) analyzed; hibiscus significantly reduced SBP by −6.67 mmHg and DBP by −4.35 mmHg vs placebo
Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults.
Hypertension (Dallas, Tex. : 1979) (2018) · Rct · n=20
Randomized, placebo-controlled, double-blind crossover trial in 20 healthy older adults (60-79 yr) with impaired endothelial function
A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society (2010) · Rct · n=128
PROTECT: multicenter double-blind RCT of 128 newly diagnosed, untreated Parkinson's patients over 12 months
The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients.
Liver international : official journal of the International Association for the Study of the Liver (2010) · Rct · n=30
Phase-II RCT: 30 chronic hepatitis-C patients randomized to mitoquinone (40 or 80 mg) or placebo once daily for 28 days
Hibiscus has a higher evidence score (6/10 vs 5/10) and wins in 2 of 3 categories.
For support heart health, Hibiscus has a higher relevance score (75 vs 60).
No known interactions between Hibiscus and MitoQ have been documented in our database. However, always consult a healthcare provider before combining supplements.